Wednesday, 12 June 2019
Friday, 7 June 2019
OTSUKA CHEMICAL SUCCEEDED PART OF THE CEFIXIME BUSINESS FROM ASTELLAS PHARMA
TOKYO, June 7 (Bernama-BUSINESS WIRE) -- Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc. (Head Office: Chuo-Ku, Tokyo; President & CEO: Kenji Yasukawa, Ph.D.; hereinafter “Astellas Pharma”).
Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.
Cefixime developed by Astellas Pharma is a third-generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria and it is extensively prescribed worldwide.
In addition to the main business field of chemicals, Otsuka Chemical will continue strengthening the manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business and CMO business by taking advantage of key technologies cultivated in the field of organic and inorganic chemicals.
http://mrem.bernama.com/viewsm.php?idm=34703
Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.
Cefixime developed by Astellas Pharma is a third-generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria and it is extensively prescribed worldwide.
In addition to the main business field of chemicals, Otsuka Chemical will continue strengthening the manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business and CMO business by taking advantage of key technologies cultivated in the field of organic and inorganic chemicals.
http://mrem.bernama.com/viewsm.php?idm=34703
Subscribe to:
Posts (Atom)